Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANNXNASDAQ:CRGXNASDAQ:HUMANASDAQ:RENB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANNXAnnexon$1.69+3.0%$2.03$1.29▼$7.85$185.42M1.241.79 million shs976,109 shsCRGXCARGO Therapeutics$4.06-0.6%$4.20$3.00▼$25.45$187.07M0.47518,929 shs268,107 shsHUMAHumacyte$1.22-0.8%$2.03$1.15▼$9.97$189.25M1.643.63 million shs1.41 million shsRENBRenovaro$0.31+7.9%$0.54$0.29▼$2.34$49.71M0.62945,475 shs919,300 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANNXAnnexon-9.12%-13.42%-2.66%-55.54%-65.80%CRGXCARGO Therapeutics-3.55%-10.13%+1.49%+9.68%-79.56%HUMAHumacyte-2.38%-13.99%-8.89%-71.40%-72.91%RENBRenovaro-9.06%-14.22%-26.08%-60.09%-80.39%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANNXAnnexon1.6527 of 5 stars3.51.00.00.01.41.70.6CRGXCARGO Therapeutics1.8971 of 5 stars2.90.00.00.02.11.71.3HUMAHumacyte2.7921 of 5 stars3.52.00.00.02.83.30.6RENBRenovaro1.1068 of 5 stars0.02.00.00.02.73.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANNXAnnexon 3.00Buy$18.671,004.54% UpsideCRGXCARGO Therapeutics 1.86Reduce$15.00269.73% UpsideHUMAHumacyte 3.00Buy$13.711,024.12% UpsideRENBRenovaro 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest RENB, CRGX, ANNX, and HUMA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/26/2025HUMAHumacyteD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.00 ➝ $25.003/12/2025HUMAHumacyteHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $15.003/7/2025HUMAHumacyteD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.00 ➝ $25.003/4/2025ANNXAnnexonNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.002/27/2025HUMAHumacyteBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy2/26/2025HUMAHumacyteD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.00 ➝ $25.00(Data available from 5/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANNXAnnexonN/AN/AN/AN/A$3.20 per shareN/ACRGXCARGO TherapeuticsN/AN/AN/AN/A$9.84 per shareN/AHUMAHumacyte$1.57M120.54N/AN/A$0.13 per share9.38RENBRenovaroN/AN/AN/AN/A$0.52 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANNXAnnexon-$134.24M-$1.02N/AN/AN/AN/A-38.99%-33.90%5/12/2025 (Estimated)CRGXCARGO Therapeutics-$98.15M-$3.72N/AN/AN/AN/A-38.16%-33.94%5/13/2025 (Estimated)HUMAHumacyte-$110.78M-$1.26N/AN/AN/AN/A-942.81%-93.82%5/9/2025 (Estimated)RENBRenovaro-$80.65M-$0.93N/A∞N/AN/A-61.84%-48.07%5/13/2025 (Estimated)Latest RENB, CRGX, ANNX, and HUMA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025CRGXCARGO Therapeutics-$0.70N/AN/AN/AN/AN/A5/12/2025Q1 2025ANNXAnnexon-$0.30N/AN/AN/AN/AN/A5/9/2025Q1 2025HUMAHumacyte-$0.19N/AN/AN/A$0.46 millionN/A3/28/2025Q4 2024HUMAHumacyte-$0.23-$0.16+$0.07-$0.16$0.64 million$7.23 million3/3/2025Q4 2024ANNXAnnexon-$0.28-$0.33-$0.05-$0.33N/AN/A2/19/2025Q2 2025RENBRenovaroN/A-$0.02N/A-$0.04N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANNXAnnexonN/AN/AN/AN/AN/ACRGXCARGO TherapeuticsN/AN/AN/AN/AN/AHUMAHumacyteN/AN/AN/AN/AN/ARENBRenovaroN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANNXAnnexonN/A17.1717.18CRGXCARGO TherapeuticsN/A18.9418.95HUMAHumacyteN/A1.101.10RENBRenovaroN/A0.060.08Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANNXAnnexonN/ACRGXCARGO Therapeutics93.16%HUMAHumacyte44.71%RENBRenovaro71.41%Insider OwnershipCompanyInsider OwnershipANNXAnnexon12.67%CRGXCARGO Therapeutics1.38%HUMAHumacyte11.20%RENBRenovaro21.72%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANNXAnnexon60109.71 million93.09 millionOptionableCRGXCARGO Therapeutics11646.11 million45.39 millionN/AHUMAHumacyte150155.12 million111.76 millionOptionableRENBRenovaro20158.72 million124.24 millionOptionableRENB, CRGX, ANNX, and HUMA HeadlinesRecent News About These CompaniesRenovaro Inc. (NASDAQ:RENB) Shares Acquired by Geode Capital Management LLCMay 2, 2025 | marketbeat.comRENB-aandeel raakt 52-weeks dieptepunt van $ 0,32 door marktuitdagingenMay 1, 2025 | nl.investing.comRenovaro BioSciences expands collaboration with NebulApril 23, 2025 | markets.businessinsider.comRenovaro Inc. Expands Collaboration with Nebul to Enhance Early Cancer Detection Through Advanced AI TechnologyApril 22, 2025 | quiverquant.comRenovaro Secures High-Powered Computing from Nebul Through a Partnership to Accelerate Next-Generation Biomarker Discovery and Diagnostic ProgramsApril 22, 2025 | globenewswire.comRenovaro riskeert Nasdaq-notering te verliezen door te lage aandelenkoersApril 18, 2025 | nl.investing.comRenovaro BioSciences, BioSymetrics close merger transactionApril 9, 2025 | markets.businessinsider.comRenovaro Inc: Renovaro and BioSymetrics Close Merger to Accelerate AI-Driven Biomarker Discovery and Precision MedicineApril 9, 2025 | finanznachrichten.deRenovaro fuseert met BioSymetrics voor AI-gedreven medicijnontwikkelingApril 9, 2025 | nl.investing.comRenovaro and BioSymetrics Close Merger to Accelerate AI-Driven Biomarker Discovery and Precision MedicineApril 9, 2025 | globenewswire.comPredictive Oncology Ends Merger Talks with RenovaroApril 7, 2025 | tipranks.comRenovaro Biosciences stuit op tegenslag bij fusie met Predictive OncologyApril 6, 2025 | nl.investing.comRenovaro Inc: Renovaro Provides Update to Definitive Agreement with Predictive OncologyApril 4, 2025 | finanznachrichten.deRenovaro BioSciences provides update to agreement with Predictive OncologyApril 4, 2025 | markets.businessinsider.comRenovaro Shares Fall After Merger SetbackApril 4, 2025 | marketwatch.comRenovaro says Predictive Oncology terminates merger transactionApril 4, 2025 | markets.businessinsider.comRenovaro Provides Update to Definitive Agreement with Predictive OncologyApril 4, 2025 | globenewswire.comRenovaro Biosciences Advances Financing for AI-Driven Integration and Strategic Expansion in Oncology through Acquisition of Predictive OncologyMarch 5, 2025 | nasdaq.comRenovaro (RENB) and Predictive Oncology Partner for AI-Driven Drug Discovery: What’s Next for Cancer and HIV Treatments?March 4, 2025 | insidermonkey.comRenovaro provides financing to Predictive Oncology as both move to finalize definitive merger agreementMarch 3, 2025 | bizjournals.comRenovaro Completes First Milestone Payment to Finalize Definitive Agreement with Predictive OncologyMarch 3, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRENB, CRGX, ANNX, and HUMA Company DescriptionsAnnexon NASDAQ:ANNX$1.69 +0.05 (+3.05%) Closing price 04:00 PM EasternExtended Trading$1.73 +0.04 (+2.37%) As of 06:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.CARGO Therapeutics NASDAQ:CRGX$4.06 -0.02 (-0.56%) Closing price 03:59 PM EasternExtended Trading$4.06 +0.00 (+0.07%) As of 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San Mateo, California.Humacyte NASDAQ:HUMA$1.22 -0.01 (-0.81%) Closing price 04:00 PM EasternExtended Trading$1.24 +0.02 (+1.64%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.Renovaro NASDAQ:RENB$0.31 +0.02 (+7.93%) Closing price 04:00 PM EasternExtended Trading$0.32 +0.01 (+3.45%) As of 07:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Renovaro Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company's product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV. It also develops RENB-DC-11, an allogeneic dendritic cell therapeutic vaccine for pancreatic cancer; RENB-DC-12-XX, an allogeneic dendritic cell therapeutic vaccine for other solid tumors; and RENB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells. It has strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. The company was formerly known as Renovaro Biosciences Inc. and changed its name to Renovaro Inc. in February 2024. Renovaro Inc. is headquartered in Los Angeles, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Disney Stock Jumps on Earnings—Is the Magic Sustainable? AMD Relieves Market Despite Ongoing Share Price Outlook Caution Gold’s Record Run in 2025: Here Are 3 Ways to Ride the Surge What the New Quarter Says About Super Micro Computer's Future Archer Stock Eyes Q1 Earnings After UAE Updates Ford Motor Stock Rises After Earnings, But Momentum May Not Last Broadcom Stock Gets a Lift on Hyperscaler Earnings & CapEx Boost Lemonade Delivers Sweet Results, Price Reversal to Accelerate Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
